inclusion criteria: 1. willing and able to give electronically signed informed consent for participation in the study. 2. male or female subject ≥18 years of age at screening. 3. women of child-bearing potential have to agree to use an acceptable birth control method during participation in the investigation and a negative pregnancy test (beta human chorionic gonadotropin dipstick test in urine) at day 1 will be required. 4. a positive pcr test (polymerase chain reaction test) or antigen test for sars-cov-2. the positive result must be available no later than 4 days from initiation of symptoms, if any. 5. duration of symptoms not exceeding 6 days prior to baseline/imp administration (day 1). 6. access to a mobile phone or computer and ability to use the electronic diary application and to participate in web-based appointments.

inclusion criteria: 1. willing and able to give electronically signed informed consent for participation in the study. 2. male or female subject ≥18 years of age at screening. 3. women of child-bearing potential have to agree to use an acceptable birth control method during participation in the investigation and a negative pregnancy test (beta human chorionic gonadotropin dipstick test in urine) at day 1 will be required. 4. a positive pcr test (polymerase chain reaction test) or antigen test for sars-cov-2. the positive result must be available no later than 4 days from initiation of symptoms, if any. 5. duration of symptoms not exceeding 6 days prior to baseline/imp administration (day 1). 6. access to a mobile phone or computer and ability to use the electronic diary application and to participate in web-based appointments.

inclusion criteria: willing and able to give electronically signed informed consent for participation in the study. male or female subject ≥18 years of age at screening. women of child-bearing potential have to agree to use an acceptable birth control method during participation in the investigation and a negative pregnancy test (beta human chorionic gonadotropin dipstick test in urine) at day 1 will be required. a positive pcr test (polymerase chain reaction test) or antigen test for sars-cov-2. the positive result must be available no later than 4 days from initiation of symptoms, if any. duration of symptoms not exceeding 6 days prior to baseline/imp administration (day 1). access to a mobile phone or computer and ability to use the electronic diary application and to participate in web-based appointments.

inclusion criteria: willing and able to give electronically signed informed consent for participation in the study. male or female subject ≥18 years of age at screening. women of child-bearing potential have to agree to use an acceptable birth control method during participation in the investigation and a negative pregnancy test (beta human chorionic gonadotropin dipstick test in urine) at day 1 will be required. a positive pcr test (polymerase chain reaction test) or antigen test for sars-cov-2. the positive result must be available no later than 4 days from initiation of symptoms, if any. duration of symptoms not exceeding 6 days prior to baseline/imp administration (day 1). access to a mobile phone or computer and ability to use the electronic diary application and to participate in web-based appointments.

inclusion criteria: 1. willing and able to give electronically signed informed consent for participation in the study. 2. male or female subject ≥18 years of age at screening. 3. women of child-bearing potential have to agree to use an acceptable birth control method during participation in the investigation and a negative pregnancy test (beta human chorionic gonadotropin dipstick test in urine) at day 1 will be required. 4. a positive pcr test (polymerase chain reaction test) or antigen test for sars-cov-2. the positive result must be available no later than 4 days from initiation of symptoms, if any. 5. duration of symptoms not exceeding 6 days prior to baseline/imp administration (day 1). 6. access to a mobile phone or computer and ability to use the electronic diary application and to participate in web-based appointments.

inclusion criteria: 1. willing and able to give electronically signed informed consent for participation in the study. 2. male or female subject ≥18 years of age at screening. 3. women of child-bearing potential have to agree to use an acceptable birth control method during participation in the investigation and a negative pregnancy test (beta human chorionic gonadotropin dipstick test in urine) at day 1 will be required. 4. a positive pcr test (polymerase chain reaction test) or antigen test for sars-cov-2. the positive result must be available no later than 4 days from initiation of symptoms, if any. 5. duration of symptoms not exceeding 6 days prior to baseline/imp administration (day 1). 6. access to a mobile phone or computer and ability to use the electronic diary application and to participate in web-based appointments.